Min Hak Lee, Ki-Hwan Um, Seok Won Lee, Ye Ji Sun, Da-Hye Gu, Young Ok Jo, Sung Hyun Kim, Wongi Seol, Hyorin Hwang, Kyunghwa Baek, Jin Woo Choi
BACKGROUND: Parthanatos represents a critical molecular aspect of Parkinson's disease, wherein AIMP2 aberrantly activates PARP-1 through direct physical interaction. Although AIMP2 ought to be a therapeutic target for the disease, regrettably, it is deemed undruggable due to its non-enzymatic nature and predominant localization within the tRNA synthetase multi-complex. Instead, AIMP2 possesses an antagonistic splice variant, designated DX2, which counteracts AIMP2-induced apoptosis in the p53 or inflammatory pathway...
January 3, 2024: Acta Neuropathologica Communications